FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295509263> ?p ?o ?g. }

• W4295509263 endingPage "693" @default.
• W4295509263 startingPage "681" @default.
• W4295509263 abstract "Abemaciclib is the most recent oral cyclin-dependent kinase 4 and 6 inhibitor (CDK4 & 6i) to receive US Food and Drug Administration (FDA) approval to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced or metastatic breast cancer (MBC). Administrative claims data were used to describe patient characteristics and select clinical and economic outcomes in US patients treated in routine clinical practice. Prior analyses from electronic health records data indicate approximately 25% of patients received either palbociclib or ribociclib for MBC before initiating abemaciclib treatment; this work further explored these findings and associated outcomes. This retrospective study analyzed medical and pharmacy claims from the IBM® MarketScan® Research Databases between 1 January 2007 to 31 January 2020. Patients with HR+, HER2− MBC newly initiating abemaciclib between 1 September 2017 and 31 October 2019 were included and grouped by concomitant therapy (+aromatase inhibitor (AI), +fulvestrant (F), 200 mg abemaciclib monotherapy (Mono), or +other), and outcomes were analyzed by prior CDK4 & 6i use. Patient and treatment characteristics were summarized with descriptive statistics. Kaplan–Meier methods assessed time-to-discontinuation (TTD; i.e., persistency) and time-to-chemotherapy (TTC). Adherence (defined by the medication possession ratio) and drug wastage were determined. This analysis included 454 patients (mean age 57.7 years), with 35.0% (n = 159) in the +F group, 29.3% (n = 133) in the +AI group, 10.4% (n = 47) in the 200 mg Mono group, and 25.3% (n = 115) in the +other group. Prior chemotherapy and CDK 4 & 6i use were present in 23.8% and 49.8% of all patients, respectively. Visceral metastases were present at abemaciclib initiation in 50.4% in the +AI group; 49.7% in the +F group; and 55.3% in the 200 mg Mono group. Liver metastases were present in 33.7% of the overall population. Among patients without prior CDK4 & 6i use, the median TTD for patients receiving abemaciclib + AI was not reached [95% CI 430–not reached (NR) days], abemaciclib + F [531 days (95% CI 281–NR)], and abemaciclib mono [141 days (95% CI 80–NR)]. Median TTC for abemaciclib + AI and abemaciclib + F groups were not reached and the median TTC for abemaciclib mono was 535 days (95% CI 181–NR). Medication adherence was 88.7% and medication wastage costs among those with at least one dose modification were $808.12 and $452.2 per patient per month based on amount paid and wholesale acquisition cost (WAC), respectively. Mean length of follow-up for all patients was 350 days (SD 187). These real-world data complement clinical trial results by examining abemaciclib use among patients treated in routine clinical practice. The sizeable number of patients treated with prior CDK4 & 6i, chemotherapy, and/or visceral metastases at abemaciclib initiation suggest that many patients had very advanced disease and/or were in later stages of their treatment. These data confirm a higher percentage of patients treated with previous CDK4 & 6i than reported previously, reinforcing the importance of the ongoing, prospective clinical trials evaluating outcomes following progression on CDK4 & 6i." @default.
• W4295509263 created "2022-09-14" @default.
• W4295509263 creator A5005185722 @default.
• W4295509263 creator A5007715634 @default.
• W4295509263 creator A5020575816 @default.
• W4295509263 creator A5080642920 @default.
• W4295509263 creator A5081919968 @default.
• W4295509263 creator A5082016998 @default.
• W4295509263 creator A5083092373 @default.
• W4295509263 creator A5091364840 @default.
• W4295509263 date "2022-09-12" @default.
• W4295509263 modified "2023-10-09" @default.
• W4295509263 title "Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2− Metastatic Breast Cancer Treated with Abemaciclib" @default.
• W4295509263 cites W2000445173 @default.
• W4295509263 cites W2015338056 @default.
• W4295509263 cites W2019876752 @default.
• W4295509263 cites W2063844762 @default.
• W4295509263 cites W2111648462 @default.
• W4295509263 cites W2112646145 @default.
• W4295509263 cites W2135785083 @default.
• W4295509263 cites W2139062201 @default.
• W4295509263 cites W2171869606 @default.
• W4295509263 cites W2204808283 @default.
• W4295509263 cites W2290950904 @default.
• W4295509263 cites W2552099557 @default.
• W4295509263 cites W2620993107 @default.
• W4295509263 cites W2735183683 @default.
• W4295509263 cites W2761290885 @default.
• W4295509263 cites W2802484510 @default.
• W4295509263 cites W2802776309 @default.
• W4295509263 cites W2805575723 @default.
• W4295509263 cites W2806677947 @default.
• W4295509263 cites W2891508744 @default.
• W4295509263 cites W2910972034 @default.
• W4295509263 cites W2912331647 @default.
• W4295509263 cites W2921007348 @default.
• W4295509263 cites W2924345863 @default.
• W4295509263 cites W2947245065 @default.
• W4295509263 cites W2947281735 @default.
• W4295509263 cites W2947574926 @default.
• W4295509263 cites W2947864495 @default.
• W4295509263 cites W2947876005 @default.
• W4295509263 cites W2965775308 @default.
• W4295509263 cites W2976415870 @default.
• W4295509263 cites W2977565884 @default.
• W4295509263 cites W3013014737 @default.
• W4295509263 cites W3021990204 @default.
• W4295509263 cites W3030183195 @default.
• W4295509263 cites W3087561595 @default.
• W4295509263 cites W3127151442 @default.
• W4295509263 cites W3137319568 @default.
• W4295509263 cites W3161555469 @default.
• W4295509263 cites W3169705417 @default.
• W4295509263 doi "https://doi.org/10.1007/s40801-022-00327-1" @default.
• W4295509263 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36097254" @default.
• W4295509263 hasPublicationYear "2022" @default.
• W4295509263 type Work @default.
• W4295509263 citedByCount "4" @default.
• W4295509263 countsByYear W42955092632023 @default.
• W4295509263 crossrefType "journal-article" @default.
• W4295509263 hasAuthorship W4295509263A5005185722 @default.
• W4295509263 hasAuthorship W4295509263A5007715634 @default.
• W4295509263 hasAuthorship W4295509263A5020575816 @default.
• W4295509263 hasAuthorship W4295509263A5080642920 @default.
• W4295509263 hasAuthorship W4295509263A5081919968 @default.
• W4295509263 hasAuthorship W4295509263A5082016998 @default.
• W4295509263 hasAuthorship W4295509263A5083092373 @default.
• W4295509263 hasAuthorship W4295509263A5091364840 @default.
• W4295509263 hasBestOaLocation W42955092631 @default.
• W4295509263 hasConcept C121608353 @default.
• W4295509263 hasConcept C126322002 @default.
• W4295509263 hasConcept C143998085 @default.
• W4295509263 hasConcept C207103383 @default.
• W4295509263 hasConcept C2775930923 @default.
• W4295509263 hasConcept C2777176818 @default.
• W4295509263 hasConcept C2778715236 @default.
• W4295509263 hasConcept C2779744173 @default.
• W4295509263 hasConcept C2780482068 @default.
• W4295509263 hasConcept C44249647 @default.
• W4295509263 hasConcept C530470458 @default.
• W4295509263 hasConcept C71924100 @default.
• W4295509263 hasConceptScore W4295509263C121608353 @default.
• W4295509263 hasConceptScore W4295509263C126322002 @default.
• W4295509263 hasConceptScore W4295509263C143998085 @default.
• W4295509263 hasConceptScore W4295509263C207103383 @default.
• W4295509263 hasConceptScore W4295509263C2775930923 @default.
• W4295509263 hasConceptScore W4295509263C2777176818 @default.
• W4295509263 hasConceptScore W4295509263C2778715236 @default.
• W4295509263 hasConceptScore W4295509263C2779744173 @default.
• W4295509263 hasConceptScore W4295509263C2780482068 @default.
• W4295509263 hasConceptScore W4295509263C44249647 @default.
• W4295509263 hasConceptScore W4295509263C530470458 @default.
• W4295509263 hasConceptScore W4295509263C71924100 @default.
• W4295509263 hasFunder F4320307758 @default.
• W4295509263 hasIssue "4" @default.
• W4295509263 hasLocation W42955092631 @default.
• W4295509263 hasLocation W42955092632 @default.
• W4295509263 hasLocation W42955092633 @default.

• next